Vise Technologies Inc. Grows Position in McKesson Corporation $MCK

Vise Technologies Inc. grew its stake in shares of McKesson Corporation (NYSE:MCK) by 113.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,471 shares of the company’s stock after purchasing an additional 2,912 shares during the quarter. Vise Technologies Inc.’s holdings in McKesson were worth $4,488,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in MCK. Brighton Jones LLC boosted its stake in shares of McKesson by 46.3% during the fourth quarter. Brighton Jones LLC now owns 2,523 shares of the company’s stock valued at $1,438,000 after purchasing an additional 798 shares during the period. Caxton Associates LLP purchased a new stake in shares of McKesson during the first quarter valued at approximately $233,000. Sivia Capital Partners LLC boosted its stake in shares of McKesson by 77.9% during the second quarter. Sivia Capital Partners LLC now owns 685 shares of the company’s stock valued at $502,000 after purchasing an additional 300 shares during the period. Treasurer of the State of North Carolina boosted its stake in shares of McKesson by 0.9% during the second quarter. Treasurer of the State of North Carolina now owns 58,623 shares of the company’s stock valued at $42,958,000 after purchasing an additional 508 shares during the period. Finally, Osterweis Capital Management Inc. purchased a new stake in shares of McKesson during the second quarter valued at approximately $166,000. Hedge funds and other institutional investors own 85.07% of the company’s stock.

McKesson Stock Up 2.6%

Shares of MCK stock opened at $776.51 on Friday. The stock has a fifty day moving average of $806.32 and a 200 day moving average of $848.96. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00. The firm has a market capitalization of $93.34 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 1.25 and a beta of 0.31.

McKesson (NYSE:MCK) last announced its quarterly earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping analysts’ consensus estimates of $11.56 by $0.13. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The company had revenue of $96.30 billion during the quarter, compared to analyst estimates of $101.35 billion. During the same quarter last year, the firm posted $10.12 earnings per share. The firm’s revenue was up 6.0% on a year-over-year basis. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Equities research analysts anticipate that McKesson Corporation will post 44.27 earnings per share for the current year.

McKesson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 1st. Shareholders of record on Monday, June 1st will be issued a $0.82 dividend. The ex-dividend date is Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a yield of 0.4%. McKesson’s dividend payout ratio is 8.53%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MCK. UBS Group increased their price objective on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Weiss Ratings lowered McKesson from a “buy (b+)” rating to a “buy (b)” rating in a research note on Monday, May 18th. Raymond James Financial set a $970.00 price target on McKesson in a research note on Thursday, March 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $875.00 price target on shares of McKesson in a research note on Friday, May 8th. Finally, William Blair started coverage on McKesson in a research note on Tuesday, April 28th. They issued an “outperform” rating for the company. Fourteen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $968.87.

Insiders Place Their Bets

In other McKesson news, EVP Thomas L. Rodgers sold 2,388 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total value of $1,817,482.92. Following the completion of the transaction, the executive vice president owned 3,090 shares in the company, valued at approximately $2,351,768.10. This represents a 43.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Michele Lau sold 3,550 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total value of $2,701,869.50. Following the completion of the transaction, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $2,471,259.23. This trade represents a 52.23% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 6,760 shares of company stock valued at $5,123,773. 0.08% of the stock is owned by corporate insiders.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.